You are here

  • Home
  • Archive
  • Volume 65, Issue 9
  • Diagnostic accuracy of the γ-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Diagnostic accuracy of the γ-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4
  1. Yusuke Shimakawa1,
  2. Philippe Bonnard2,
  3. Mohamed El Kassas3,
  4. Mohamed Abdel-Hamid4,5,
  5. Gamal Esmat6,
  6. Arnaud Fontanet1,7
  1. 1 Unité d’Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France
  2. 2 Infectious Diseases, Hôpital Tenon (AP-HP), Paris, France
  3. 3 Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
  4. 4 Department of Microbiology, Faculty of Medicine, Minia University, El Minia, Egypt
  5. 5 Viral Hepatitis Research Laboratory, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
  6. 6 Endemic Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt
  7. 7 Département d'Infection et Epidémiologie, Conservatoire National des Arts et Métiers, Paris, France
  1. Correspondence to Dr Arnaud Fontanet, Unité d’Épidémiologie des Maladies Émergentes, Institut Pasteur, 25 rue du Docteur Roux, Paris 75015, France; fontanet{at}pasteur.fr

https://doi.org/10.1136/gutjnl-2016-312326

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Given the high disease burden with viral hepatitis, and the advent of highly effective direct-acting antivirals against HCV infection, the WHO is now developing a global strategy to eliminate viral hepatitis by 2030.1 Increasing the uptake of HCV diagnosis and treatment will become a key intervention in achieving this goal.

    Although antiviral drugs should be considered for all persons with chronic HCV infection, those with significant liver fibrosis, and especially cirrhosis, should be prioritised for treatment, as they are at increased risk of hepatic complications. Current WHO guidelines for HCV recommend aspartate aminotransferase (AST)-to-platelet ratio index (APRI) or Fib-4 for the fibrosis assessment in low/middle-income countries (LMIC), because of their low cost and wide availability.2 Recently, Lemoine et al 3 developed a novel simple index called γ-glutamyl transpeptidase (GGT) to platelet …

    View Full Text

    Footnotes

    • Funding ANRS (12184).

    • Competing interests None declared.

    • Ethics approval National Hepatology and Tropical Medicine Research Institute Ethics Committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.